We evaluate the reliability of routine sextant prostate biopsy to detect unilateral lesions. A total of 365 men with complete records including all clinical and pathologic variables who underwent a preoperative sextant biopsy and subsequent radical prostatectomy (RP) for clinically localized prostate cancer at our medical center between January 1996 and December 2006 were identified. When the sextant biopsy detects unilateral disease, according to RP results, the NPV is high (91%) with a low false negative rate (9%). However, the sextant biopsy has a PPV of 28% with a high false positive rate (72%). Therefore, a routine sextant prostate biopsy cannot provide reliable, accurate information about the unilaterality of tumor lesion(s).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urolonc.2009.03.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing the Performance of Artificial Intelligence Assistance for Prostate MRI: A Two-Center Study Involving Radiologists With Different Experience Levels.
J Magn Reson Imaging
November 2024
Department of Radiology, Peking University First Hospital, Beijing, China.
Background: Artificial intelligence (AI) assistance may enhance radiologists' performance in detecting clinically significant prostate cancer (csPCa) on MRI. Further validation is needed for radiologists with different experiences.
Purpose: To assess the performance of experienced and less-experienced radiologists in detecting csPCa, with and without AI assistance.
Targeted Ablation Using Ultrasound-Guided Irreversible Electroporation of Index Tumors (TARGET Study): Prospective Development Study Evaluating Safety, Patient-Reported Outcomes, and Oncologic Efficacy.
Urol Pract
November 2024
Memorial Sloan Kettering Cancer Center, Department of Surgery, Urology Division, New York, New York.
Article Synopsis
- The study assessed the safety, patient-reported functional outcomes, and effectiveness of focal irreversible electroporation as a primary treatment for intermediate-risk prostate cancer.
- Between February 2015 and April 2017, 20 patients underwent this treatment, with results indicating no significant deterioration in urinary or sexual function six months post-treatment.
- At the 12-month mark, a significant portion of patients (74%) had no clinically significant cancer, with a radical treatment-free survival rate of 79% at two years, suggesting that the treatment could be beneficial for selected patients.
Image-guided multiparametric magnetic resonance imaging-transrectal ultrasound fusion biopsy augmented with a sextant versus an extended template random biopsy: Comparison of cancer detection rates, complication and functional outcomes.
Prostate
September 2024
Department of Urologic Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Purpose: To compare the efficacy of a novel fusion template "reduced six-core systemic template and multiparametric magnetic resonance imaging/transrectal ultrasound (mpMRI/TRUS) fusion targeted biopsy" (TBx+6c), with mpMRI/TRUS fusion-targeted biopsy and 12-core systematic biopsy template (TBx+12c) in the diagnosis of prostate cancer (PCa).
Materials And Methods: This is an institutional review board approved single-center observational study involving adult men undergoing fusion-targeted biopsies for the diagnosis of PCa. Patients were sorted into cohorts of TBx+6c or TBx+12c based on the systematic biopsy template used.
Clinical significance of location of perineural cancer invasion detected on prostate needle core biopsy.
Virchows Arch
March 2024
Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
The clinical impact of site-specific perineural invasion (PNI) in prostate cancer remains poorly understood. We compared radical prostatectomy findings and oncologic outcomes in 434 patients with single-site PNI on systematic sextant biopsy. PNI was present in the right apex (n = 62; 14%), right mid (n = 70; 16%), right base (n = 89; 21%), left apex (n = 64; 15%), left mid (n = 58; 13%), and left base (n = 91; 21%).
View Article and Find Full Text PDFCumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era.
Prostate
June 2024
Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Background: To validate the use of a cumulative cancer locations (CCLO) score, a measurement of tumor volume on biopsy, and to develop a novel magnetic resonance imaging (MRI)-informed CCLO (mCCLO) score to predict clinical outcomes on active surveillance (AS).
Methods: The CCLO score is a sum of uniquely involved sextants with prostate cancer on diagnostic + confirmatory biopsy. The mCCLO score incorporates MRI findings into the CCLO score.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!